Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Pregabalin
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Generic legal battle == *2012, Pfizer blocked multiple drug manufacturers from selling pregabalin, a generic version of Pfizer's drug Lyrica.<ref name=":2">{{Cite news | url=https://www.reuters.com/article/pfizer-lyrica-ruling-idUSL2E8IJJQV20120719| title = Court upholds Pfizer's Lyrica patent protection | last = | first = | date = 2012-07-19|work=Reuters|access-date=2021-03-09|archive-url=|archive-date=|url-status=|language=en|quote=}}</ref> *July 2012, the U.S. [[Food and Drug Administration]] (FDA) approved a generic version of Lyrica. Pregabalin, the active ingredient, is the generic name.<ref>{{Cite news | url=https://www.reuters.com/article/us-lupin-lyrica-idUSBRE8640Y220120705| title = U.S. OKs Lupin generic of Pfizer nerve pain drug | last = | first = | date = 2012-07-05|work=Reuters|access-date=2021-03-09|archive-url=|archive-date=|url-status=|language=en|quote=}}</ref> Two weeks after being approved by the FDA, marketing was blocked by Pfizer.<ref name=":2" /> *2014, Pfizer Inc., the maker of Lyrica, successfully blocked the marketing of Pregabalin generics until December of 2018 arguing that the generics should not be marketed and made available until their patent ran out.<ref>{{Cite news | url=https://www.bloomberg.com/news/articles/2014-02-06/pfizer-wins-ruling-to-block-generic-lyrica-until-2018| title = Pfizer Wins Ruling to Block Generic Lyrica Until 2018 | last = Decker | first = Susan | date = Feb 6, 2014|work=Bloomberg Business|access-date=|archive-url=|archive-date=|url-status=}}</ref> Warner-Lamber, (a subsidiary of Pfizer), "still holds a “second medical use” patent for the use of pregabalin in the treatment of peripheral and central neuropathic pain, which expires in July 2017. A second medical use patent is one that relates to a new medical use for a known compound."<ref>{{Cite journal | last = Wise | first = Jacqui | date = 2015-03-30| title = Doctors are warned not to prescribe generic pregabalin for pain control|url=https://www.bmj.com/content/350/bmj.h1724|journal=BMJ|language=en|volume=350|pages=h1724|doi=10.1136/bmj.h1724|issn=1756-1833|pmid=25825288}}</ref> * Nov 2018, [https://investors.pfizer.com/investor-news/press-release-details/2018/Pfizer-Receives-Six-Months-Pediatric-Exclusivity-for-LYRICA-pregabalin/default.aspx Pfizer Receives Six Months Pediatric Exclusivity For Lyrica® (Pregabalin)]<ref name=":02">{{Cite web|url=https://investors.pfizer.com/investor-news/press-release-details/2018/Pfizer-Receives-Six-Months-Pediatric-Exclusivity-for-LYRICA-pregabalin/default.aspx| title = Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin) | last = | first = | authorlink = | date = Nov 27, 2018 | website = investors.pfizer.com|language=en-US|archive-url=|archive-date=|url-status=|access-date=2018-12-27}}</ref> <blockquote>Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for LYRICA<sup>®</sup>. This grant extends the period of U.S. market exclusivity for LYRICA by an additional six months, to June 30, 2019.<ref name=":02" /></blockquote> * July 22, 1019, FDA approves first generics of Lyrica<ref name=":1">{{Cite web|url=http://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-lyrica | title = FDA approves first generics of Lyrica | last = Commissioner | first=Office of the | date = 2019-09-11 | website = FDA|language=en|access-date=2019-10-11}}</ref> <blockquote>On July 19, the [[U.S. Food and Drug Administration]] approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of [[fibromyalgia]], and for the management of neuropathic pain associated with [[spinal cord]] injury.<ref name=":1" /></blockquote>
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs